Bone Biologics (NASDAQ:BBLG) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Bone Biologics (NASDAQ:BBLG) issued its earnings results on Friday. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.04), FiscalAI reports.

Bone Biologics Stock Performance

NASDAQ BBLG traded down $0.02 during trading on Friday, reaching $0.66. 167,161 shares of the company’s stock were exchanged, compared to its average volume of 142,196. The company has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $1.25. The stock has a market cap of $1.19 million, a P/E ratio of -0.29 and a beta of 0.92. Bone Biologics has a 1 year low of $0.62 and a 1 year high of $4.13.

Institutional Investors Weigh In On Bone Biologics

An institutional investor recently raised its stake in Bone Biologics stock. DRW Securities LLC lifted its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.